Pensionfund Sabic Makes New Investment in Amgen Inc. $AMGN

Pensionfund Sabic bought a new stake in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,400 shares of the medical research company’s stock, valued at approximately $2,422,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Perennial Advisors LLC boosted its holdings in Amgen by 3.0% in the 4th quarter. Perennial Advisors LLC now owns 19,956 shares of the medical research company’s stock valued at $6,532,000 after purchasing an additional 579 shares during the last quarter. Arlington Financial Advisors LLC increased its holdings in shares of Amgen by 1.8% during the 4th quarter. Arlington Financial Advisors LLC now owns 25,799 shares of the medical research company’s stock worth $8,444,000 after buying an additional 444 shares during the last quarter. Quantum Financial Advisors LLC increased its holdings in shares of Amgen by 25.0% during the 4th quarter. Quantum Financial Advisors LLC now owns 4,050 shares of the medical research company’s stock worth $1,326,000 after buying an additional 811 shares during the last quarter. Avanza Fonder AB raised its position in shares of Amgen by 12.5% during the 4th quarter. Avanza Fonder AB now owns 64,357 shares of the medical research company’s stock valued at $21,065,000 after buying an additional 7,150 shares during the period. Finally, Salem Investment Counselors Inc. raised its position in shares of Amgen by 3.5% during the 4th quarter. Salem Investment Counselors Inc. now owns 29,934 shares of the medical research company’s stock valued at $9,798,000 after buying an additional 1,016 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Down 0.4%

Shares of NASDAQ AMGN opened at $348.43 on Wednesday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The business’s 50 day moving average is $361.26 and its two-hundred day moving average is $329.06. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The firm has a market cap of $187.83 billion, a price-to-earnings ratio of 24.49, a PEG ratio of 3.47 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the business posted $5.31 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.84%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on AMGN shares. Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a research report on Tuesday, January 20th. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Jefferies Financial Group began coverage on Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target on the stock. Rothschild & Co Redburn increased their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Finally, Royal Bank Of Canada raised their price objective on Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.